CD19 CAR NK-Cell Therapy Achieves Significant Response in Patients with Leukemia, Lymphoma
March 9th 2020Treatment with cord blood-derived chimeric antigen receptor natural killer-cell therapy targeting CD19 resulted in clinical responses in relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Read More